The US Food and Drug Administration has approved The Medicines Company’s Kengreal (cangrelor), an intravenous antiplatelet small-molecule drug that prevents formation of blood clots in the coronary arteries. It is approved for adult patients undergoing percutaneous coronary intervention (PCI), a procedure used to open a blocked or narrowed coronary artery to improve blood flow to the heart muscle.

The Medicines Company focuses on developing drugs in three main areas: serious infectious disease care, acute cardiovascular care, and surgery and perioperative care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers in Parsippany, New Jersey and Zurich, Switzerland.

Source: FDA and The Medicines Company